Aliases & Classifications for Laryngeal Disease

Summaries for Laryngeal Disease

MalaCards based summary : Laryngeal Disease, also known as laryngeal diseases, is related to larynx cancer and laryngitis, and has symptoms including dyspnea and stridor. An important gene associated with Laryngeal Disease is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and testes.

Related Diseases for Laryngeal Disease

Diseases related to Laryngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 larynx cancer 28.9 MIRLET7B MIRLET7A1 MIR93 MIR423 MIR34C MIR34A
2 laryngitis 11.4
3 miyoshi muscular dystrophy 1 10.6 MIR34A MIR21 MIR148A
4 dermatomyositis 10.6 MIR34A MIR21 MIR148A
5 esophagus adenocarcinoma 10.5 MIR21 MIR196A1 MIR143
6 bladder carcinoma in situ 10.5 MIR142 MIR139
7 heart conduction disease 10.5 MIR423 MIR21 MIR142
8 feingold syndrome 1 10.5 MIR20A MIR17 MIR106B
9 idiopathic interstitial pneumonia 10.5 MIR423 MIR21 MIR142
10 intrinsic cardiomyopathy 10.5 MIR423 MIR21 MIR142
11 acute myocardial infarction 10.5 MIR423 MIR34A MIR21 CA3
12 laryngeal squamous cell carcinoma 10.5 MIR34A MIR21 MIR148A
13 leiomyoma, uterine 10.5 MIR34A MIR27A MIR21 MIR139
14 bile duct adenocarcinoma 10.5 MIR21 MIR17 MIR142
15 facioscapulohumeral muscular dystrophy 1 10.5 MIRLET7B MIR34A MIR21
16 autoimmune disease of musculoskeletal system 10.5 MIR34A MIR21 MIR196A1 MIR142
17 thyroid gland anaplastic carcinoma 10.5 MIR34C MIR17
18 pre-malignant neoplasm 10.5 MIR17 MIR142 MIR139
19 tongue disease 10.4 MIR21 MIR196A1 MIR17 MIR139
20 cervix carcinoma 10.4 MIR34C MIR27A MIR142 MIR139
21 b-cell lymphoma 10.4 MIR21 MIR20A MIR17 MIR142
22 bronchial disease 10.4 MIR21 MIR17 MIR142
23 breast carcinoma in situ 10.4 MIR423 MIR17 MIR143 MIR142
24 aortic valve disease 2 10.4 MIR423 MIR34A MIR21 MIR17 MIR106B
25 pleural cancer 10.4 MIRLET7B MIRLET7A1 MIR17 MIR139
26 disease of mental health 10.4 MIR21 MIR17 MIR142 MIR106B
27 x-linked recessive disease 10.4 MIR27A MIR196A1 MIR142
28 retinal cancer 10.4 MIR196A1 MIR17 MIR142
29 bile duct disease 10.4 MIR196A1 MIR17 MIR148A MIR142
30 non-alcoholic fatty liver disease 10.4 MIR34A MIR27A MIR21 MIR17
31 biliary tract disease 10.4 MIR196A1 MIR17 MIR148A MIR142
32 ocular cancer 10.4 MIR34C MIR196A1 MIR17 MIR142
33 gallbladder disease 10.4 MIR17 MIR143 MIR142 MIR135A1
34 endometriosis 10.4 MIR34C MIR20A MIR143 MIR142
35 mouth disease 10.4 MIR21 MIR196A1 MIR17 MIR142
36 pediatric systemic lupus erythematosus 10.4 MIR27A MIR17
37 renal fibrosis 10.4 MIR21 MIR196A1 MIR135A1
38 pulmonary fibrosis, idiopathic 10.4 MIR423 MIR34C MIR21 MIR196A1 MIR142
39 x-linked monogenic disease 10.4 MIR27A MIR196A1 MIR142
40 laryngeal benign neoplasm 10.3 MIR21 MIR106B
41 glioma 10.3 MIR34A MIR21 MIR20A MIR17
42 clear cell renal cell carcinoma 10.3 MIRLET7A1 MIR21 MIR149 MIR106B
43 chromosomal disease 10.3 MIR196A1 MIR17 MIR142
44 kidney cancer 10.3 MIR27A MIR21 MIR20A MIR17 MIR106B
45 infratentorial cancer 10.3 MIR34C MIR27A MIR20A MIR17 MIR142
46 autosomal genetic disease 10.3 MIR21 MIR20A MIR196A1 MIR17 MIR142
47 mature b-cell neoplasm 10.3 MIRLET7B MIR196A1 MIR17 MIR148A MIR142
48 inherited metabolic disorder 10.3 MIR21 MIR17 MIR142
49 ovarian serous carcinoma 10.3 MIRLET7B MIR93 MIR27A MIR21 MIR20A MIR143
50 pancreatic ductal adenocarcinoma 10.3 MIR93 MIR21 MIR196A1 MIR148A MIR143 MIR142

Graphical network of the top 20 diseases related to Laryngeal Disease:



Diseases related to Laryngeal Disease

Symptoms & Phenotypes for Laryngeal Disease

UMLS symptoms related to Laryngeal Disease:


dyspnea, stridor

Drugs & Therapeutics for Laryngeal Disease

Drugs for Laryngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3 Gastrointestinal Agents Phase 4
4 Anti-Ulcer Agents Phase 4
5 Proton Pump Inhibitors Phase 4
6 Antacids Phase 4
7
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
8
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
9
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
10
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
11
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
12
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
15 Vitamins Phase 3
16 Hypolipidemic Agents Phase 3
17 Vitamin B Complex Phase 3
18 Vitamin B3 Phase 3
19 Folate Phase 3
20 Vitamin B9 Phase 3
21 Lipid Regulating Agents Phase 3
22 Nicotinic Acids Phase 3
23 Vasodilator Agents Phase 3
24 Antineoplastic Agents, Immunological Phase 2, Phase 3
25 Antimitotic Agents Phase 2, Phase 3
26 Immunologic Factors Phase 2, Phase 3
27 Antibodies, Monoclonal Phase 2, Phase 3
28 Antibodies Phase 2, Phase 3
29 Immunoglobulins Phase 2, Phase 3
30 Neurotransmitter Agents Phase 2, Phase 3
31 Tranquilizing Agents Phase 2, Phase 3
32 Antipsychotic Agents Phase 2, Phase 3
33 Analgesics, Non-Narcotic Phase 2, Phase 3
34 Psychotropic Drugs Phase 2, Phase 3
35 Amitriptyline, perphenazine drug combination Phase 2, Phase 3
36 Antidepressive Agents Phase 2, Phase 3
37 Central Nervous System Depressants Phase 2, Phase 3
38 Adrenergic Agents Phase 2, Phase 3
39 Analgesics Phase 2, Phase 3
40 Antidepressive Agents, Tricyclic Phase 2, Phase 3
41
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
42
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
43
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
44
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46 Raspberry Approved Phase 1, Phase 2
47
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
50
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 An Interdisciplinary Interpretation of Transnasal Esophagoscopy Findings Completed NCT00372918 Phase 4
2 Do Laryngeal Biopsy Findings Predict Treatment Response in Suspected Laryngopharyngeal Reflux Completed NCT00444145 Phase 4 Prevacid
3 Role of Esophageal and Laryngeal Biopsies in Suspected Laryngopharyngeal Reflux Completed NCT00373997 Phase 4
4 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
5 A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma. Completed NCT00147732 Phase 3
6 Randomized Placebo-Controlled Trial of BID Lansoprazole in Isolated Chronic Post Nasal Drip Completed NCT00335283 Phase 3 Lansoprazole Tablet;lansoprazole;placebo
7 PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS Completed NCT00002839 Phase 3 cisplatin;fluorouracil
8 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
9 Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline Enrolling by invitation NCT02552225 Phase 2, Phase 3 Amitriptyline
10 Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitryptiline Terminated NCT02434523 Phase 2, Phase 3 Amitriptyline
11 Effect of Aggressive Acid Suppression With Esomeprazole on Vocal Cord Granulomas: Randomized Placebo-Controlled Trial Withdrawn NCT00567658 Phase 3 Esomeprazole
12 Left, Right, or Bilateral Thalamic Deep Brain Stimulation for Voice Tremor: A Prospective, Randomized, Double-Blinded Trial Unknown status NCT02960243 Phase 1, Phase 2
13 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
14 Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity Completed NCT01733823 Phase 1, Phase 2
15 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
16 Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx Completed NCT00508664 Phase 2 Cetuximab;Docetaxel;Cisplatin (TP);5-Fluorouracil (TPF) (only until Feb 2009)
17 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
18 A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx Completed NCT02055989 Phase 1, Phase 2
19 A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Completed NCT00098631 Phase 2 lapatinib ditosylate
20 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
21 Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma Completed NCT00387335 Phase 2 sunitinib malate
22 A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors Completed NCT00063895 Phase 1, Phase 2 erlotinib hydrochloride
23 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
24 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
25 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
26 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
27 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
28 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
29 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
30 A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck Completed NCT00055913 Phase 1, Phase 2 erlotinib hydrochloride
31 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
32 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
33 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
34 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
35 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
36 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
37 Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00410826 Phase 2 erlotinib hydrochloride;cisplatin
38 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
39 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
40 Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck Active, not recruiting NCT01884259 Phase 2 Docetaxel;Cisplatin;5-fluorouracil
41 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck Terminated NCT01682031 Phase 2 cisplatin
42 A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation Terminated NCT00895245 Phase 2 fosaprepitant dimeglumine;cisplatin;palonosetron hydrochloride;dexamethasone
43 A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Terminated NCT01192815 Phase 2 erlotinib hydrochloride
44 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
45 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
46 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
47 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
48 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
49 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
50 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel

Search NIH Clinical Center for Laryngeal Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Laryngeal Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Laryngeal Disease:
Laviv azficel-T, dermal fibroblasts for scarring
Embryonic/Adult Cultured Cells Related to Laryngeal Disease:
Skin-derived fibroblasts PMIDs: 21287562 10805306 23211390

Cochrane evidence based reviews: laryngeal diseases

Genetic Tests for Laryngeal Disease

Anatomical Context for Laryngeal Disease

MalaCards organs/tissues related to Laryngeal Disease:

40
Thyroid, Lung, Testes, Breast, Bone, Brain, Liver

Publications for Laryngeal Disease

Articles related to Laryngeal Disease:

(show top 50) (show all 440)
# Title Authors PMID Year
1
Laryngeal Disease in Dogs and Cats: An Update. 61
31882166 2020
2
The future of robotic surgery in otolaryngology - head and neck surgery. 61
31841882 2020
3
Multi-Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis. 61
30963598 2020
4
The Use of 532-Nanometer-Pulsed Potassium-Titanyl-Phosphate (KTP) Laser in Laryngology: A Systematic Review of Current Indications, Safety, and Voice Outcomes. 61
31928082 2020
5
Characteristics of Functional Dysphonia in Children. 61
30172669 2020
6
Original Research: Aerosolized Lidocaine: Effective for Safer Arousal After Suspension Laryngoscopy. 61
30227980 2020
7
Laryngeal amyloidosis. 61
31651423 2019
8
Direct Visualization of Laryngeal Mucociliary Clearance in Adults. 61
31271035 2019
9
Exploring stimulation patterns for electrical stimulation of the larynx using surface electrodes. 61
31414223 2019
10
Infection Rates After Microlaryngeal and Open Phonosurgery: The Role of Postoperative Antibiotics. 61
31424561 2019
11
Clinical and radiographic findings in cats with aspiration pneumonia: retrospective evaluation of 28 cases. 61
30843218 2019
12
Discrimination of "hot potato voice" caused by upper airway obstruction utilizing a support vector machine. 61
30485441 2019
13
Protective effect of aerobic exercise on the vocal folds against cigarette smoke exposure. 61
30980189 2019
14
Method for Vertical Calibration of Laser-Projection Transnasal Fiberoptic High-Speed Videoendoscopy. 61
31151853 2019
15
Laryngeal metastases from breast cancer: A rare clinical entity. 61
30119910 2019
16
Magnetic resonance imaging of the larynx in the pediatric population: A systematic review. 61
30680950 2019
17
Diagnostic Accuracy of Dysphonia Classification of DSI and AVQI. 61
30203473 2019
18
Anatomy and Pathology of the Texel Sheep Larynx. 61
30818827 2019
19
Visible Vessels of Vocal Folds: Can they have a Diagnostic Role? 61
32008546 2019
20
[Surgical treatment of laryngeal cysts in children with argonplasma coagulation]. 61
32027321 2019
21
HPV infection and clinical profiles in laryngeal diseases. A preliminary study. 61
31814599 2019
22
Laryngeal reconstruction in children with recurrent respiratory papillomatosis. 61
30368371 2018
23
Proposal of a form for the collection of videolaryngostroboscopy basic findings. 61
29789936 2018
24
Detecting Laryngopharyngeal Reflux by Immunohistochemistry of Pepsin in the Biopsies of Vocal Fold Leukoplakia. 61
28756936 2018
25
[Laryngopharyngeal Reflux]. 61
29635668 2018
26
[Current status and prospect of photodynamic therapy in laryngeal diseases]. 61
29747260 2018
27
[Reconstruction of the examination of the laryngeal carcinoma of Emperor Frederick III by Rudolf Virchow]. 61
29147845 2018
28
Pediatric head and neck squamous cell carcinoma: Patient demographics, treatment trends and outcomes. 61
29447885 2018
29
Effective Glottal Instant Detection and Electroglottographic Parameter Extraction for Automated Voice Pathology Assessment. 61
28103563 2018
30
Platelet indices in laryngeal cancer. 61
29286923 2018
31
[Laryngeal disease. Endoscopic characterization of 1493 procedures based on age]. 61
29368893 2018
32
Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. 61
28945296 2017
33
A cat with suspected laryngeal metastasis with mucosal irregularity resulting from apocrine/salivary gland adenocarcinoma in the head. 61
29021425 2017
34
A link between RelB expression and tumor progression in laryngeal cancer. 61
29371965 2017
35
A Case Series of the Probability Density and Cumulative Distribution of Laryngeal Disease in a Tertiary Care Voice Center. 61
28949246 2017
36
Reinnervation of the diaphragm by the inferior laryngeal nerve to the phrenic nerve in ventilator-dependent tetraplegic patients with C3-5 damage. 61
29181382 2017
37
Comparative characteristics of laryngeal-resident mesenchymal stromal cell populations isolated from distinct sites in the rat larynx. 61
28962587 2017
38
Laryngeal manifestations of pachyonychia congenita: a clinical case and discussion on management for the otolaryngologist. 61
27762179 2017
39
Human Papillomavirus Infection Status of Various Laryngeal Diseases in Japan: A Comprehensive Study. 61
27986378 2017
40
Association of endotracheal tube repositioning and acute laryngeal lesions during mechanical ventilation in children. 61
28439690 2017
41
Persistent Lobar Atelectasis in a Patient With Chronic Hoarseness. 61
28483133 2017
42
Laryngeal T regulatory cells in the setting of smoking and reflux. 61
27653511 2017
43
Manoeuvres to Improve Endoscopic Visualization of Hypopharynx. 61
28239587 2017
44
Health-related Quality of Life as Studied by EORTC QLQ and Voice Handicap Index Among Various Patients With Laryngeal Disease. 61
27520510 2017
45
Clinical features and surgical treatment for Chinese juvenile onset current respiratory papillomatosis (JORRP). 61
27637752 2017
46
A predictive test for difficult intubation in laryngeal microsurgery. Validation study. 61
27592722 2017
47
Use of concurrent chemoradiation in advanced staged (T4) laryngeal cancer. 61
27838151 2017
48
The risk factors of intraoperative anesthesia adverse events in children with laryngeal diseases. 61
27687447 2016
49
Do Talkativeness and Vocal Loudness Correlate With Laryngeal Pathology? A Study of the Vocal Overdoer/Underdoer Continuum. 61
26311493 2016
50
A Population-Based Cross-Sectional Study of Alcohol Consumption and Risk of Benign Laryngeal Disease in Korean Adults. 61
26810937 2016

Variations for Laryngeal Disease

Expression for Laryngeal Disease

Search GEO for disease gene expression data for Laryngeal Disease.

Pathways for Laryngeal Disease

Pathways related to Laryngeal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIRLET7B MIRLET7A1 MIR423 MIR34C MIR34A MIR27A
2 11.36 MIR34C MIR20A MIR17
3 11.05 MIRLET7A1 MIR93 MIR34C MIR27A MIR106B
4 10.9 MIRLET7B MIRLET7A1 MIR34C MIR148A

GO Terms for Laryngeal Disease

Cellular components related to Laryngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 MIRLET7B MIRLET7A1 MIR93 MIR423 MIR27A MIR21

Biological processes related to Laryngeal Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.88 MIR27A MIR21 MIR20A MIR17
2 positive regulation of angiogenesis GO:0045766 9.84 MIRLET7B MIR21 MIR20A MIR143
3 cellular response to hypoxia GO:0071456 9.79 MIR34A MIR17 MIR106B
4 negative regulation of angiogenesis GO:0016525 9.78 MIR34A MIR21 MIR143 MIR106B
5 negative regulation of protein kinase B signaling GO:0051898 9.73 MIR34C MIR34A MIR20A
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.69 MIR21 MIR20A MIR106B
7 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.67 MIR27A MIR20A MIR196A1
8 positive regulation of vascular endothelial cell proliferation GO:1905564 9.63 MIR27A MIR21
9 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.63 MIR21 MIR20A MIR143
10 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.62 MIRLET7B MIR27A
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MIR27A MIR21 MIR20A MIR17
12 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR34A MIR21
13 negative regulation of cholesterol efflux GO:0090370 9.61 MIR27A MIR148A
14 negative regulation of stress fiber assembly GO:0051497 9.61 MIR21 MIR20A MIR149
15 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.6 MIR21 MIR17
16 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.59 MIR34A MIR17
17 positive regulation of connective tissue replacement GO:1905205 9.58 MIR34C MIR34A
18 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR27A MIR17 MIR148A
19 positive regulation of metalloendopeptidase activity GO:1904685 9.57 MIR21 MIR17
20 negative regulation of sprouting angiogenesis GO:1903671 9.56 MIR34C MIR34A MIR20A MIR17
21 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
22 gene silencing by miRNA GO:0035195 9.55 MIRLET7B MIRLET7A1 MIR93 MIR423 MIR34C MIR34A
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR34C MIR20A MIR17
24 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.52 MIRLET7B MIR21
25 miRNA mediated inhibition of translation GO:0035278 9.5 MIRLET7A1 MIR27A MIR21 MIR20A MIR17 MIR148A
26 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.33 MIR20A MIR17 MIR143

Molecular functions related to Laryngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.53 MIRLET7B MIRLET7A1 MIR93 MIR423 MIR34A MIR27A

Sources for Laryngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....